BR112023003548A2 - Vírus adenoassociado para liberação de kh902 (conbercept) e usos do mesmo - Google Patents
Vírus adenoassociado para liberação de kh902 (conbercept) e usos do mesmoInfo
- Publication number
- BR112023003548A2 BR112023003548A2 BR112023003548A BR112023003548A BR112023003548A2 BR 112023003548 A2 BR112023003548 A2 BR 112023003548A2 BR 112023003548 A BR112023003548 A BR 112023003548A BR 112023003548 A BR112023003548 A BR 112023003548A BR 112023003548 A2 BR112023003548 A2 BR 112023003548A2
- Authority
- BR
- Brazil
- Prior art keywords
- variants
- conbercept
- adeno
- release
- vegf
- Prior art date
Links
- 241000702421 Dependoparvovirus Species 0.000 title abstract 2
- 108700036276 KH902 fusion Proteins 0.000 title abstract 2
- 229950005748 conbercept Drugs 0.000 title abstract 2
- 241000702423 Adeno-associated virus - 2 Species 0.000 abstract 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 abstract 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 241001164825 Adeno-associated virus - 8 Species 0.000 abstract 1
- 108090000565 Capsid Proteins Proteins 0.000 abstract 1
- 102100023321 Ceruloplasmin Human genes 0.000 abstract 1
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 abstract 1
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 abstract 1
- 108700019146 Transgenes Proteins 0.000 abstract 1
- 230000001594 aberrant effect Effects 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 230000002137 anti-vascular effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 230000011664 signaling Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14171—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Ophthalmology & Optometry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063074361P | 2020-09-03 | 2020-09-03 | |
| US202163179700P | 2021-04-26 | 2021-04-26 | |
| PCT/US2021/048917 WO2022051537A1 (en) | 2020-09-03 | 2021-09-02 | Adeno-associated virus for delivery of kh902 (conbercept) and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023003548A2 true BR112023003548A2 (pt) | 2023-04-04 |
Family
ID=80491540
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023003548A BR112023003548A2 (pt) | 2020-09-03 | 2021-09-02 | Vírus adenoassociado para liberação de kh902 (conbercept) e usos do mesmo |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230340529A1 (https=) |
| EP (1) | EP4208478A4 (https=) |
| JP (1) | JP2023540094A (https=) |
| KR (1) | KR20230061441A (https=) |
| AU (1) | AU2021336425A1 (https=) |
| BR (1) | BR112023003548A2 (https=) |
| CA (1) | CA3192736A1 (https=) |
| IL (1) | IL300864A (https=) |
| MX (1) | MX2023002695A (https=) |
| WO (1) | WO2022051537A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2020006435A (es) | 2017-12-19 | 2021-02-09 | Akouos Inc | Administracion de anticuerpos terapeuticos mediada por vector de virus adenoasociado (aav) en el oido interno. |
| IL303317A (en) | 2020-12-01 | 2023-07-01 | Akouos Inc | ANTI-NATURAL ANTIBODY STRUCTURES AND RELATED METHODS FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH VESTIBULAR SWANNOMA |
| AU2024247959A1 (en) * | 2023-03-28 | 2025-10-09 | General Medicines Llc | Nucleic acid off-switches and methods and uses thereof |
| WO2024220389A2 (en) * | 2023-04-17 | 2024-10-24 | University Of Massachusetts | Aav2 variants and uses thereof |
| CN119656336A (zh) * | 2023-09-21 | 2025-03-21 | 成都弘基生物科技有限公司 | 一种重组腺相关病毒在制备治疗与血管新生相关眼病的药物中的用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100897379B1 (ko) * | 2004-06-08 | 2009-05-14 | 쳉두 캉홍 바이오테크놀로지스 코. 리미티드 | 혈관신생-저해 키메릭 단백질 및 그 사용 |
| AU2014286996A1 (en) * | 2013-07-12 | 2016-01-07 | Iveric Bio, Inc. | Methods for treating or preventing ophthalmological conditions |
| EP3134522B1 (en) * | 2014-04-25 | 2021-10-06 | University of Massachusetts | Recombinant aav vectors useful for reducing immunity against transgene products |
| US11046955B2 (en) * | 2015-04-24 | 2021-06-29 | University Of Massachusetts | Modified AAV constructs and uses thereof |
| DK3471780T3 (da) * | 2016-06-16 | 2020-11-23 | Adverum Biotechnologies Inc | Behandling af amd med aav2-variant med aflibercept |
| AU2018227483A1 (en) * | 2017-02-28 | 2019-09-12 | Adverum Biotechnologies, Inc. | Modified AAV capsids and uses thereof |
| AU2018350990A1 (en) * | 2017-10-18 | 2020-05-21 | Regenxbio Inc. | Treatment of ocular diseases and metastatic colon cancer with human post-translationally modified VEGF-Trap |
| KR102205830B1 (ko) * | 2017-10-26 | 2021-01-21 | 주식회사 큐로진생명과학 | 솔루블 VEGFR-1 변이체 cDNA를 함유하는 rAAV를 포함하는 황반변성 치료용 조성물 |
| US11103552B2 (en) * | 2018-05-10 | 2021-08-31 | Regeneron Pharmaceuticals, Inc. | High concentration VEGF receptor fusion protein containing formulations |
-
2021
- 2021-09-02 BR BR112023003548A patent/BR112023003548A2/pt unknown
- 2021-09-02 MX MX2023002695A patent/MX2023002695A/es unknown
- 2021-09-02 CA CA3192736A patent/CA3192736A1/en active Pending
- 2021-09-02 WO PCT/US2021/048917 patent/WO2022051537A1/en not_active Ceased
- 2021-09-02 JP JP2023514415A patent/JP2023540094A/ja active Pending
- 2021-09-02 KR KR1020237010791A patent/KR20230061441A/ko active Pending
- 2021-09-02 AU AU2021336425A patent/AU2021336425A1/en active Pending
- 2021-09-02 EP EP21865133.9A patent/EP4208478A4/en active Pending
- 2021-09-02 IL IL300864A patent/IL300864A/en unknown
- 2021-09-02 US US18/024,359 patent/US20230340529A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2023002695A (es) | 2023-05-19 |
| WO2022051537A1 (en) | 2022-03-10 |
| EP4208478A4 (en) | 2025-04-02 |
| CA3192736A1 (en) | 2022-03-10 |
| EP4208478A1 (en) | 2023-07-12 |
| IL300864A (en) | 2023-04-01 |
| JP2023540094A (ja) | 2023-09-21 |
| US20230340529A1 (en) | 2023-10-26 |
| AU2021336425A1 (en) | 2023-03-16 |
| KR20230061441A (ko) | 2023-05-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112023003548A2 (pt) | Vírus adenoassociado para liberação de kh902 (conbercept) e usos do mesmo | |
| Zeitler et al. | Allele-selective transcriptional repression of mutant HTT for the treatment of Huntington’s disease | |
| Chicoine et al. | Plasmapheresis eliminates the negative impact of AAV antibodies on microdystrophin gene expression following vascular delivery | |
| US9352021B2 (en) | Systems, compositions, and methods for transplantation and treating conditions | |
| ES2661500T3 (es) | Variantes de HMGB1 y sus usos | |
| BR112018072849A2 (pt) | capsídeos variantes de vírus adeno associado e métodos de uso | |
| CL2019002474A1 (es) | Vector clado f de virus adeno-asociado (vaa) y usos relacionados. | |
| JP2021519791A (ja) | 増強されたヒト膵臓トロピズムを有する新規な組換えアデノ随伴ウイルスキャプシド | |
| Sutherland et al. | Reovirus neurotropism and virulence are dictated by sequences in the head domain of the viral attachment protein | |
| BR112022004027A2 (pt) | Métodos para tratar doenças neovasculares oculares usando variantes de aav2 que codificam aflibercepte | |
| JP6782701B2 (ja) | 脳疾患を処置するための方法および組成物 | |
| Huda et al. | Fusion of human fetal mesenchymal stem cells with “degenerating” cerebellar neurons in spinocerebellar ataxia type 1 model mice | |
| US20240075109A1 (en) | Telomerase reverse transcriptase-based therapies | |
| BR112023019056A2 (pt) | Métodos para tratar doenças oculares usando variantes de aav2 que codificam aflibercepte | |
| Kim et al. | Combination of three angiogenic growth factors has synergistic effects on sprouting of endothelial cell/mesenchymal stem cell‐based spheroids in a 3D matrix | |
| UY38881A (es) | Métodos de tratamiento de enfermedades neovasculares oculares utilizando variantes de aav2 que codifican aflibercept | |
| Jollé et al. | Development of efficient AAV2/DJ-based viral vectors to selectively downregulate the expression of neuronal or astrocytic target proteins in the rat central nervous system | |
| Gruntman et al. | Bridging from intramuscular to limb perfusion delivery of rAAV: optimization in a non-human primate study | |
| CN110168085A (zh) | 用脐带血移植(ucbt)和增加的半乳糖脑苷酯酶(galc)表达治疗克拉伯病 | |
| WO2018183705A1 (en) | Oxidation-resistant aat gene therapy | |
| KR20250017245A (ko) | 아데노 관련 바이러스 약학적 조성물 및 이의 용도 | |
| AU2017358282A1 (en) | Nkx3.2 fragment and pharmaceutical composition comprising same as active ingredient | |
| FI3177313T3 (fi) | Telomeraasi-käänteistranskriptaasipohjaisia hoitoja sydäninfarktiin liittyvien tilojen hoitamiseksi | |
| BR112022003206A2 (pt) | Métodos para tratar doenças neovasculares oculares usando variantes de aav2 que codificam aflibercepte | |
| JP2025508336A (ja) | Ｔｐｋを発現する組換えウイルスおよびアルツハイマー病の処置におけるその使用 |